Market Overview

Hearing Wedbush Names Omeros Top Pick for 2014; $32 PT

Share:
Related OMER
Omeros Announces FDA Grants Fast Track Designation to Complement Inhibitor OMS721 for aHUS
Omidria Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

Latest Ratings for OMER

DateFirmActionFromTo
Feb 2014McNicoll Lewis VlakMaintainsBuy
Apr 2013WBB SecuritiesMaintainsStrong Buy
Apr 2013MLV & Co.Initiates Coverage onBuy

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings Movers

 

Related Articles (OMER)

Get Benzinga's Newsletters